Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide

Robert M. Dean, Brad Pohlman, John W. Sweetenham, Ronald M. Sobecks, Matt E. Kalaycio, Stephen D. Smith, Edward A. Copelan, Steven Andresen, Lisa A. Rybicki, Julie Curtis, Brian J. Bolwell

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Autologous stem cell transplantation (ASCT) with cyclophosphamide, etoposide and oral busulfan (BuCyVP) is an effective therapy for relapsed or refractory non-Hodgkin lymphoma (NHL). Substituting intravenous for oral busulfan reduces variability in drug exposure, potentially improving the safety and efficacy of the BuCyVP regimen. We retrospectively compared the outcomes of 604 consecutively treated patients who underwent ASCT for NHL with BuCyVP using oral (n = 468) or IV (n = 136) busulfan, without measurement of busulfan levels for pharmacokinetic (PK) analysis. Patients who received oral busulfan experienced more severe oral mucositis and a higher incidence of nonrelapse mortality. Median overall survival (OS) after ASCT was 72 months with oral busulfan but was not reached for the IV busulfan group. IV busulfan was associated with a lower rate of relapse, and superior relapse-free survival (RFS) and OS. In multivariate models, the route of busulfan administration was an independent prognostic factor for relapse (P = 0·01), RFS (P = 0·002) and OS (P = 0·001). IV busulfan appears to provide better efficacy and lower toxicity than oral busulfan in ASCT with BuCyVP for NHL. Whether PK-based busulfan dosing can achieve further improvements in this setting is worthy of study.

Original languageEnglish (US)
Pages (from-to)226-234
Number of pages9
JournalBritish Journal of Haematology
Volume148
Issue number2
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Busulfan
Stem Cell Transplantation
Etoposide
Non-Hodgkin's Lymphoma
Cyclophosphamide
Survival
Recurrence
Pharmacokinetics
Stomatitis

Keywords

  • Autologous stem cell transplantation
  • Mucositis
  • Non-Hodgkin lymphoma
  • Relapse
  • Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. / Dean, Robert M.; Pohlman, Brad; Sweetenham, John W.; Sobecks, Ronald M.; Kalaycio, Matt E.; Smith, Stephen D.; Copelan, Edward A.; Andresen, Steven; Rybicki, Lisa A.; Curtis, Julie; Bolwell, Brian J.

In: British Journal of Haematology, Vol. 148, No. 2, 01.01.2010, p. 226-234.

Research output: Contribution to journalArticle

Dean, Robert M. ; Pohlman, Brad ; Sweetenham, John W. ; Sobecks, Ronald M. ; Kalaycio, Matt E. ; Smith, Stephen D. ; Copelan, Edward A. ; Andresen, Steven ; Rybicki, Lisa A. ; Curtis, Julie ; Bolwell, Brian J. / Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. In: British Journal of Haematology. 2010 ; Vol. 148, No. 2. pp. 226-234.
@article{2f80eaf036824578bec38b50e3ac528c,
title = "Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide",
abstract = "Autologous stem cell transplantation (ASCT) with cyclophosphamide, etoposide and oral busulfan (BuCyVP) is an effective therapy for relapsed or refractory non-Hodgkin lymphoma (NHL). Substituting intravenous for oral busulfan reduces variability in drug exposure, potentially improving the safety and efficacy of the BuCyVP regimen. We retrospectively compared the outcomes of 604 consecutively treated patients who underwent ASCT for NHL with BuCyVP using oral (n = 468) or IV (n = 136) busulfan, without measurement of busulfan levels for pharmacokinetic (PK) analysis. Patients who received oral busulfan experienced more severe oral mucositis and a higher incidence of nonrelapse mortality. Median overall survival (OS) after ASCT was 72 months with oral busulfan but was not reached for the IV busulfan group. IV busulfan was associated with a lower rate of relapse, and superior relapse-free survival (RFS) and OS. In multivariate models, the route of busulfan administration was an independent prognostic factor for relapse (P = 0·01), RFS (P = 0·002) and OS (P = 0·001). IV busulfan appears to provide better efficacy and lower toxicity than oral busulfan in ASCT with BuCyVP for NHL. Whether PK-based busulfan dosing can achieve further improvements in this setting is worthy of study.",
keywords = "Autologous stem cell transplantation, Mucositis, Non-Hodgkin lymphoma, Relapse, Survival",
author = "Dean, {Robert M.} and Brad Pohlman and Sweetenham, {John W.} and Sobecks, {Ronald M.} and Kalaycio, {Matt E.} and Smith, {Stephen D.} and Copelan, {Edward A.} and Steven Andresen and Rybicki, {Lisa A.} and Julie Curtis and Bolwell, {Brian J.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1111/j.1365-2141.2009.07940.x",
language = "English (US)",
volume = "148",
pages = "226--234",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide

AU - Dean, Robert M.

AU - Pohlman, Brad

AU - Sweetenham, John W.

AU - Sobecks, Ronald M.

AU - Kalaycio, Matt E.

AU - Smith, Stephen D.

AU - Copelan, Edward A.

AU - Andresen, Steven

AU - Rybicki, Lisa A.

AU - Curtis, Julie

AU - Bolwell, Brian J.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Autologous stem cell transplantation (ASCT) with cyclophosphamide, etoposide and oral busulfan (BuCyVP) is an effective therapy for relapsed or refractory non-Hodgkin lymphoma (NHL). Substituting intravenous for oral busulfan reduces variability in drug exposure, potentially improving the safety and efficacy of the BuCyVP regimen. We retrospectively compared the outcomes of 604 consecutively treated patients who underwent ASCT for NHL with BuCyVP using oral (n = 468) or IV (n = 136) busulfan, without measurement of busulfan levels for pharmacokinetic (PK) analysis. Patients who received oral busulfan experienced more severe oral mucositis and a higher incidence of nonrelapse mortality. Median overall survival (OS) after ASCT was 72 months with oral busulfan but was not reached for the IV busulfan group. IV busulfan was associated with a lower rate of relapse, and superior relapse-free survival (RFS) and OS. In multivariate models, the route of busulfan administration was an independent prognostic factor for relapse (P = 0·01), RFS (P = 0·002) and OS (P = 0·001). IV busulfan appears to provide better efficacy and lower toxicity than oral busulfan in ASCT with BuCyVP for NHL. Whether PK-based busulfan dosing can achieve further improvements in this setting is worthy of study.

AB - Autologous stem cell transplantation (ASCT) with cyclophosphamide, etoposide and oral busulfan (BuCyVP) is an effective therapy for relapsed or refractory non-Hodgkin lymphoma (NHL). Substituting intravenous for oral busulfan reduces variability in drug exposure, potentially improving the safety and efficacy of the BuCyVP regimen. We retrospectively compared the outcomes of 604 consecutively treated patients who underwent ASCT for NHL with BuCyVP using oral (n = 468) or IV (n = 136) busulfan, without measurement of busulfan levels for pharmacokinetic (PK) analysis. Patients who received oral busulfan experienced more severe oral mucositis and a higher incidence of nonrelapse mortality. Median overall survival (OS) after ASCT was 72 months with oral busulfan but was not reached for the IV busulfan group. IV busulfan was associated with a lower rate of relapse, and superior relapse-free survival (RFS) and OS. In multivariate models, the route of busulfan administration was an independent prognostic factor for relapse (P = 0·01), RFS (P = 0·002) and OS (P = 0·001). IV busulfan appears to provide better efficacy and lower toxicity than oral busulfan in ASCT with BuCyVP for NHL. Whether PK-based busulfan dosing can achieve further improvements in this setting is worthy of study.

KW - Autologous stem cell transplantation

KW - Mucositis

KW - Non-Hodgkin lymphoma

KW - Relapse

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=72649087456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72649087456&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07940.x

DO - 10.1111/j.1365-2141.2009.07940.x

M3 - Article

C2 - 19821828

AN - SCOPUS:72649087456

VL - 148

SP - 226

EP - 234

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -